Jaguar Animal Health (JAGX)
(Delayed Data from NSDQ)
$1.41 USD
-0.35 (-19.89%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.42 +0.01 (0.71%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Jaguar Animal Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 12 | 4 | 9 | 6 |
Cost Of Goods | 2 | 2 | 2 | 3 | 4 |
Gross Profit | 8 | 10 | 2 | 6 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 44 | 43 | 33 | 31 |
Income After Depreciation & Amortization | -34 | -34 | -41 | -27 | -29 |
Non-Operating Income | -1 | -1 | -3 | -4 | -4 |
Interest Expense | 6 | 13 | 8 | 3 | 6 |
Pretax Income | -42 | -48 | -53 | -34 | -39 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -1 | -1 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -42 | -48 | -53 | -34 | -39 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -41 | -47 | -53 | -34 | -39 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -20 | -34 | -22 | -22 |
Depreciation & Amortization (Cash Flow) | 16 | 14 | 7 | 5 | 7 |
Income After Depreciation & Amortization | -34 | -34 | -41 | -27 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.38 | 0.02 | 0.01 | 0.00 | 0.00 |
Diluted EPS Before Non-Recurring Items | -107.83 | -2,179.52 | -5,344.69 | NA | NA |
Diluted Net EPS (GAAP) | -107.83 | -2,179.52 | -5,344.69 | NA | NA |
Fiscal Year end for Jaguar Animal Health, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 2.35 | 2.30 | 2.81 | 2.68 |
Cost Of Goods | NA | 0.43 | 0.69 | 0.51 | 0.49 |
Gross Profit | NA | 1.92 | 1.61 | 2.30 | 2.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.13 | 9.17 | 11.09 | 10.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.21 | -7.56 | -8.79 | -8.10 |
Non-Operating Income | NA | -0.54 | -1.50 | 1.38 | -0.74 |
Interest Expense | NA | 0.61 | 0.25 | 0.50 | 3.45 |
Pretax Income | NA | -9.37 | -9.31 | -7.90 | -12.29 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.14 | -0.14 | -0.13 | -0.14 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.37 | -9.31 | -7.90 | -12.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.23 | -9.17 | -7.78 | -12.15 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.64 | NA | 0.34 | 0.48 |
Diluted EPS Before Non-Recurring Items | NA | -3.61 | NA | -22.89 | -25.30 |
Diluted Net EPS (GAAP) | NA | -3.61 | 100.60 | -22.89 | -41.57 |